Background--Adherence to evidence-based guidelines is an important quality indicator; yet, there is lack of assessment of adherence to performance measures in acute ischemic stroke for most world regions.
S
troke is the second leading cause of death worldwide. More than 6 million people died of stroke in 2015, with nearly 90% of these deaths in low-and middle-income countries. 1, 2 According to the World Health Organization, these numbers are expected to rise without proper intervention. The stroke burden in China has increased over the past 3 decades and has now become the leading cause of mortality, resulting in 1.6 million deaths per year. 3, 4 In contrast, the stroke burden and mortality rates have declined in many high-income countries. 5 For instance, stroke recently declined from the third to the fifth leading cause of death in the United States, largely attributable to improved prevention and acute stroke care. 6 In an effort to overcome the global stroke pandemic, the World Health Organization and United Nations declaration has called for a 25% relative reduction in premature mortality from noncommunicable diseases including stroke by the year 2025. 7, 8 Given the high mortality rates and chance of stroke recurrence, there is an urgent need to improve both acute stroke care and secondary prevention efforts. This should include measures to ensure adherence to evidence-based stroke care at both the acute phase and after discharge. Quality improvement programs such as the American Heart Association/American Stroke Association (AHA/ASA) Get With The Guidelines--Stroke (GWTG-Stroke) have been shown to improve quality of care and outcomes for patients with strokes. 9, 10 However, little is known about standardized quality-of-care measures in other nations, especially in the developing world with different racial/ethnic composition and healthcare systems. Furthermore, international comparisons of disease presentation and adherence to evidence-based quality measures may identify gaps and yield actionable insights to guide changes in policy and clinical practice. Therefore, the objective of this study was to compare patient characteristics and performance measures among patients with acute ischemic stroke in China, the largest middleincome economy, and the United States, the largest highincome economy in the world. Comparison of these 2 countries is facilitated by the presence of harmonized reporting measures in the China National Stroke Registry (CNSR) and the GWTG-Stroke registry.
Methods
The authors declare that all supporting data are available within the article. Because of a lack of research infrastructure and anticipated low volumes, community hospitals with fewer than 100 beds and rural hospitals did not participate in the registry. Research coordinators at each CNSR phase II hospital were trained to review the medical notes daily and identify, obtain informed consent from, and enroll consecutive patients with stroke. Data were collected using an internet-based patient data management tool for each eligible hospitalized case. Because many data elements in CNSR phase II were developed and adapted from the GWTG-Stroke registry, the overlap reporting systems allow a head-to-head comparison of characteristics, disease presentation, and patterns of stroke care between US and Chinese patients.
GWTG-Stroke and CNSR Phase II

Quality-of-Care Definitions
The GWTG-Stroke program developed a set of process-based measures to quantify the quality of care for patients with stroke. These include 7 evidence-based performance measures (3 acute and 4 discharge measures) and 4 quality measures and exclude patients with documented contraindications or other exceptions to treatment eligibility.
Clinical Perspective
What Is New?
• Adherence to evidence-based guidelines is an important indicator of hospital stroke care quality.
• This international comparison study found significant differences in adherence to stroke performance measures between China and the United States with regard to stroke thrombolytic therapy, deep venous thrombosis prophylaxis, anticoagulation for atrial fibrillation, lipid treatment, and rehabilitation assessment.
What Are the Clinical Implications?
• We identified suboptimal care in acute stroke treatment and secondary prevention in China, representing potential targets for quality improvement.
• National efforts are needed to improve evidence-based stroke care and outcomes. Discharge performance measures
1. Antithrombotic medication (antiplatelet or anticoagulant) prescribed at discharge ("discharge antithrombotics"). 2. Anticoagulation prescribed at discharge in patients with documented atrial fibrillation ("anticoagulation for atrial fibrillation"). 3. Lipid-lowering medication prescribed at discharge to patients with low-density lipoprotein >100 mg/dL, or those treated with lipid-lowering agents before admission, or in whom low-density lipoprotein was not documented ("low-density lipoprotein 100").
Smoking cessation intervention (counseling or medication)
at or before discharge for patients who are current smokers ("smoking cessation").
Other quality measures
1. Door-to-computed tomography time ≤25 minutes. 2. Door-to-needle time ≤60 minutes in patients treated with intravenous tissue plasminogen activator. 3. Dysphagia screening before any oral intake. 4. Stroke rehabilitation assessment.
These measures have been adopted in CNSR phase II using the same definitions. While not as comprehensive as the World Stroke Organization stroke quality indicators, these parameters are also covered by the World Stroke Organization guidelines and represent the core elements of stroke care from hyperacute phase, acute inpatient care, to secondary prevention and rehabilitation. 7 
Statistical Analysis
Baseline characteristics and performance measures were compared between Chinese and US patients with stroke using standardized difference. Unlike t and chi-square tests, the standardized difference is not dependent on sample size. Importantly, only aggregated data such as mean, variance, and percent are used for standardized difference calculation without the need for individual-level data sharing.
For binary variables:
For continuous variables: 
Results
Baseline Characteristics and In-Hospital Treatment
A total of 19 604 patients with acute ischemic stroke from 219 participating centers in CNSR phase II and 194 876 patients from 1548 sites in the GWTG-Stroke registry between June 2012 and January 2013 were included in this analysis. Compared with US hospitals, the median hospital bed size (1000 versus 367) and stroke volume (447 versus 217) were higher in China (Table 1) . Nearly 60% of patients were cared for in academic centers in both China and the United States. Divided by regions in China, the East (59.8%) had the largest number of patients, followed by Central (22.8%), and West (17.4%), which was consistent with the country's uneven population distribution. 
Performance and Quality Measures
Adherence to each individual performance and quality measure is shown in Table 2 . Early and discharge antithrombotics, smoking cessation counseling, and dysphagia screening were fairly high (>80%) in both countries, although slightly lower in China than in the United States. Substantial gaps existed between China and the United States, respectively, with regard to administration of tissue-type plasminogen activator in patients arriving within 2 hours of symptom onset (18.3% versus 83.6%), deep venous thrombosis prophylaxis (65.0% versus 97.8%), anticoagulation for atrial fibrillation (21.0% versus 94.4%), lipid-lowering treatment (66.3% versus 95.8%), door-to-needle time ≤60 minutes (14.6% versus 48.0%), and rehabilitation assessment (58.8% versus 97.4%). In contrast, door-to-computed tomography time ≤25 minutes was relatively low in both countries (China versus the United States, 26.4% versus 27.9%, respectively).
Discussion
This study is among the first international comparisons of patient characteristics and patterns of adherence with evidence-based performance measures in ischemic stroke. We found clinically significant differences in baseline characteristics among patients presenting with acute ischemic stroke in China and the United States. Importantly, we identified differences in both acute treatment and secondary prevention for ischemic stroke in China among CNSR phase II hospitals compared with the United States among hospitals participating in GWTG-Stroke, representing potential targets for quality improvement.
Our findings suggest that Chinese patients with stroke, on average, are 7 years younger than US patients. Although Chinese patients have a lower prevalence of comorbidities, medical history of previous stroke/transient ischemic attack and cigarette smoking have been reported more often in the Chinese population. Importantly, among those who had atrial fibrillation, hypertension, or dyslipidemia, Chinese patients were less likely to receive treatment for these conditions before stroke. While we are unable to determine the etiology of stroke, these data suggest that high-risk health behaviors and inadequate treatment for both primary and secondary prevention may have partially explained the early onset of stroke in the Chinese population. In addition, we found that once patients in China experienced symptoms of a stroke, they were less likely to use an ambulance, more likely to arrive by taxi or private vehicle, and have delays in hospital arrival. Potential reasons for this observation include lack of awareness of stroke symptoms, inadequate financial and geographic coverage for an ambulance, traffic condition, or patient preferences. While we cannot determine the exact reasons, public health campaigns may help educate the public about the symptoms of stroke, overcome the reluctance to seek medical attention, and emphasize the importance of getting to a hospital quickly. Regional strategies and policies to improve availability and access to emergency medical services may also be considered.
Importantly, we found significant gaps in use of evidencebased treatment among patients with acute ischemic stroke in China. Part of these differences could be explained by the different availability of stroke unit care (13.3% in China versus 71.8% in the United States). Despite similar (and longer) doorto-computed tomography time in both countries, use of intravenous thrombolytics in China was less than one third of the treatment rate in the United States (2.5% versus 8.1%). Among those who arrived within 2 hours of symptom onset, <20% Chinese patients received stroke thrombolytic therapy in China as compared with nearly 85% in the United States. Even among Chinese patients who were treated, they experienced significant delays in treatment with a median door-to-needle time of nearly 100 minutes and <15% treated within 60 minutes of hospital arrival. A previous evaluation of CNSR phase I between 2007 and 2008 identified reasons for low thrombolytic use and treatment delays. These included the need for and delays associated with informed consent, delays in laboratory testing, the necessity for patients to buy tissue-type plasminogen activator first, reduced risk tolerance for bleeding complications, medication cost, and distrust of physicians and the healthcare system. 13, 15 Overall, 2.4% of patients in CNSR phase I received thrombolytic treatment with a median door-to-needle time of 116 minutes, as compared with 2.5% and 95 minutes in CNSR phase II 5 years later between 2012 and 2013. Along with the previous reports, these findings suggest that future efforts should focus on reducing delays in patient arrival to increase the portion of patients with ischemic stroke eligible for treatment and reducing in-hospital delay to improve the timeliness of thrombolytic therapy. In addition, policy initiatives and healthcare reform are needed to improve universal healthcare coverage, increase access to certified stroke centers/stroke unit care, and reduce out-of-pocket costs for catastrophic emergency conditions such as stroke.
Aside from thrombolytic therapy, our study shows that adherence to other performance and quality measures were Based on these findings, the AHA/ASA and the Chinese Stroke Association launched a quality improvement program "Improve Stroke Care in China" in March 2018. Adapted from the AHA/ASA GWTG-Stroke, the program is designed to improve treatment for, and prevention of, cardiovascular and stroke events by helping hospitals and providers consistently adhere to treatment guidelines. This program aims to address the need for emergency medical services and prehospital caregiver education, reduce door-to-needle times for patients to receive stroke thrombolytic therapy, and increase awareness and application of endovascular reperfusion therapies and secondary stroke prevention in eligible patients.
Study Limitations
Our study has several limitations. First, both CNSR phase II and GWTG-Stroke did not collect specific information regarding the etiology of stroke, such as TOAST (Trial of Org 10172 in Acute Stroke Treatment) classification. Thus, we were unable to classify the subtypes of acute ischemic stroke as small-vessel disease and lacunar infarction, which are more prevalent in Asian patients. Second, despite being the largest stroke registries in both countries, participation in CNSR phase II and GWTG-Stroke are voluntary. There is potential selection bias introduced by the informed consent process in the Chinese stroke registry. The observed findings may not be representative of patients treated in hospitals not participating in the registry or individuals not providing informed consent. Because of the lack of small communities and rural hospitals in the registry, participating centers in CNSR phase II generally had more resources and stroke expertise. It is anticipated that the overall quality of care at the national level may be overestimated based on these high-volume and experienced centers. Nevertheless, the actual gaps in adherence to evidence-based performance measures could be even larger, further highlighting the need for improving quality of stroke care at the national level. Third, we used standardized differences to quantify the differences in characteristics and stroke performance measures. While this method uses aggregate data only without the need of individual patient data sharing, risk adjustment cannot be performed without such information. However, it could be argued that risk adjustment may not be necessary because performance measures only apply to eligible patients. Fourth, the data from both counties are dependent on the quality and accuracy of the documentation in the medical record and abstraction. Fifth, the data from both countries are 5 years old. The quality of stroke care has likely improved in both countries since 2013. Yet, given the minimum improvement, if any, in stroke thrombolytic therapy between CNSR phases I and II, there is likely room for further improvement, especially in the area of acute stroke treatment and secondary stroke prevention. A related issue is endovascular thrombectomy, although not widely adopted during our study period, endovascular thrombectomy has become the standard of care for largevessel occlusion. 16 Further study is needed to examine quality of care and outcomes of endovascular thrombectomy in both countries. 17 Finally, although we observed significant gaps in adherence to evidence-based performance measures, the registry did not document potential causes for suboptimal stroke care. To address this limitation, we plan to conduct a nationwide hospital survey in China to understand the common reasons and barriers for underuse of acute and secondary stroke prevention treatment, such as thrombolytics and oral anticoagulation for atrial fibrillation. These data will help us develop quality improvement interventions to improve evidence-based stroke treatment in China.
Conclusions
We found clinically important differences in patient characteristics and adherence to stroke performance measures between China and the United States. National efforts are needed to improve evidence-based stroke care and outcomes in both countries, especially China.
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